EPM2A
Reaktivität: Human
WB
Wirt: Maus
Polyclonal
unconjugated
Applikationshinweise
ELISA. Western blot (1: 1,000 - 1: 2,000). Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
1.0 mg/mL
Buffer
PBS, pH 7.4, containing 0.09 % sodium azide
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
4 °C/-20 °C
Informationen zur Lagerung
Store the antibody undiluted at 2-8 °C for up to two weeks or (in aliquots) at -20 °C forlonger. Avoid repeated freezing and thawing. Shelf life: one year from despatch.
Haltbarkeit
12 months
Target
EPM2A
(Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A))
Epilepsy, progressive myoclonus type 2A (EPM2A), also known as laforin, is a dual-specificity phosphatase that associates with polyribosomes. The protein may be involved in the control of glycogen metabolism, particularly in monitoring for and preventing the formation of poorly branched glycogen molecules. Defects in EPM2A are a cause of progressive myoclonic epilepsy type 2(EPM2), also known as Lafora disease. EPM2 is an autosomal recessive and severe form of adolescent-onset progressive epilepsy.Synonyms: EC=3.1.3.16, EC=3.1.3.48, EPM2A, LAFPTPase, Lafora PTPase, Laforin